TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02693652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: * Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: * Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: * Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: * Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection
Study: NCT01316588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plastic adesive drape
Description: Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbial Sealant
Description: Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
Study: NCT02736526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recession or resection of the horizontal extraocular muscles
Study: NCT03492580

Intervention type: DRUG
Intervention: Canagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Canagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
Study: NCT01358643

Intervention type: OTHER
Group type: OTHER
Intervention: Three home-based diet and exercise programs
Description: All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program.

Intervention type: OTHER
Group type: OTHER
Intervention: Three home-based diet and exercise programs
Description: All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program.

Intervention type: OTHER
Group type: OTHER
Intervention: Three home-based diet and exercise programs
Description: All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program.
Study: NCT02826759

Intervention type: OTHER
Intervention: diabetes
Description: the exposure of interests are obesity, diabetes and insulin-resistance
Study: NCT03492580

Intervention type: DRUG
Intervention: Empagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
Study: NCT02826759

Intervention type: OTHER
Intervention: diabetes
Description: the exposure of interests are obesity, diabetes and insulin-resistance

Intervention type: OTHER
Intervention: diabetes
Description: the exposure of interests are obesity, diabetes and insulin-resistance

Intervention type: OTHER
Intervention: diabetes
Description: the exposure of interests are obesity, diabetes and insulin-resistance
Study: NCT03441737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Exercise
Description: 20 minutes of sitting in the laboratory with access to magazines and the internet.
Study: NCT04913857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24-week SUDOKU Training Programme
Description: 12-week face-to-face training session and a 12-week facilitated self-practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm (wait-list)
Description: wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
Study: NCT00547560

Intervention type: DRUG
Group type: OTHER
Intervention: GSI-953
Description: Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
Study: NCT03689010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid foam 15%
Description: Azelaic acid foam 15%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea® (Azelaic acid Foam) 15%
Description: Azelaic acid foam 15%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of the test product
Description: Vehicle of the test product
Study: NCT03421925

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic totally extraperitoneal procedure for inguinal hernia
Description: Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
Study: NCT04635241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Inhaled nebulised 6 hourly
Study: NCT05347602

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gold Factor (Gold Nanoparticles, AuNPs)
Description: AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold Factor (Gold Nanoparticles, AuNPs)
Description: AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
Study: NCT03492580

Intervention type: DRUG
Intervention: Anti-hyperglycemic Agents (AHA)
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.

Intervention type: DRUG
Intervention: Anti-hyperglycemic Agents (AHA)
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.

Intervention type: DRUG
Intervention: Thiazolidinediones (TZD)
Description: No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.

Intervention type: DRUG
Intervention: Thiazolidinediones (TZD)
Description: No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.

Intervention type: DRUG
Intervention: Sulfonylureas (SU)
Description: No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide

Intervention type: DRUG
Intervention: Sulfonylureas (SU)
Description: No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide

Intervention type: DRUG
Intervention: Insulin
Description: No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Insulin
Description: No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
Study: NCT02268019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tourniquet application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine injection
Study: NCT01945554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical nerve root infiltration
Description: 4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar nerve root infiltration
Description: 40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephamesone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Bupivacain®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Bupivacain®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenacort®
Study: NCT02433535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
Study: NCT03573115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-Benzoyl Peroxide Gel 0.1-2.5%
Description: Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
Study: NCT00357474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: lipiodol, adriamycin and/or mitomycin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ethanol injection therapy
Description: 99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
Study: NCT04395131

Intervention type: DEVICE
Group type: OTHER
Intervention: Clearum HF Hemodialyzer
Description: the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
Study: NCT01438333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus brevis tablets
Description: 5 tablets a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 5 tablets a day for 6 weeks
Study: NCT02026882

Intervention type: DEVICE
Group type: OTHER
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
Study: NCT04157361

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath condensate
Description: Breath condensate will be collected from the patients involved in study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath condensate
Description: Breath condensate will be collected from the patients involved in study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath condensate
Description: Breath condensate will be collected from the patients involved in study.
Study: NCT04758559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myfood24
Description: An app to support monitoring of food and nutrient intake using robust validated methodology.
Study: NCT02044510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules to the intervention arm
Study: NCT04368546

Intervention type: DRUG
Intervention: Sunitinib
Study: NCT03362242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARO-AAT Injection
Description: Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
Study: NCT03626402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning for the Care You Want
Description: 25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
Study: NCT04309383

Intervention type: DIAGNOSTIC_TEST
Intervention: ShuntCheck
Description: The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
Study: NCT00077207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00836225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline
Study: NCT03362242

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT04167488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphic measurement
Description: Physical activity assessed with actigraphic device worn during 7 days
Study: NCT00836225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Description: 4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline
Study: NCT03016884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Description: After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Description: After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
Study: NCT01920074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment 0.4%
Study: NCT03841721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid oral tablet 300 mg/day for 5 day
Description: Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
Study: NCT03569020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subsidy for food purchases and dietitian education
Description: $105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
Study: NCT03264066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
Study: NCT03693131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent (MND-2119)
Description: Icosapent (MND-2119) capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent (MND-2119)
Description: Icosapent (MND-2119) capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent (EPADEL CAPSULES 300)
Description: Icosapent (EPADEL CAPSULES 300) capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent (EPADEL CAPSULES 300)
Description: Icosapent (EPADEL CAPSULES 300) capsules.
Study: NCT03390023

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.